Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis

Archives of Dermatological Research

Volumn 297, Issue 6, 2005, Pages 266-273

  Paquet, Philippe ^a   Jacob, Eric ^a   Damas, Pierre ^a   Pirson, Jean ^b   Piérard, Gérald ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b QUEEN ASTRID MILITARY HOSPITAL   (Belgium)

Author keywords

Cyclosporin A; Immunoglobulin; Toxic epidermal necrolysis

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 13A; CD45RO ANTIGEN; CHLORDANE; CYCLOSPORIN A; FAS ANTIGEN; FAS ANTIGEN RECEPTOR; IMMUNOGLOBULIN; SANDOGOBULINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMIS; EPIDERMIS; EPITHELIZATION; FEMALE; GENE EXPRESSION; HISTOLOGY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; INTENSIVE CARE UNIT; MACROPHAGE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN BIOPSY; SKIN NECROSIS; STANDARD; T LYMPHOCYTE; TOXIC EPIDERMAL NECROLYSIS;

ADULT; AGED; ANTIGENS, CD95; APOPTOSIS; CYCLOSPORINE; DERMIS; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED;

EID: 28244502055     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00403-005-0607-3     Document Type: Article

References (32)

1. Arevalo J, Lorente JA, Gonzalez-Herrada C, Jimenez-Reyes J (2000) Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma Inj Inf Crit Care 48:473-478
2. Bachot N, Revuz J, Roujeau JC (2003) Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 139:33-36
3. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P (2000) SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 45:149-153
4. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC (1993) Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol 129:92-96
5. Becker DS (1998) Toxic epidermal necrolysis. Lancet 351:1417-1420
6. Frangogiannis NG, Boridy F, Mazhar M, Mathews R, Gangopadhyay S, Cate T (1996) Cyclophosphamide in the treatment of toxic epidermal necrolysis. South Med J 89:1001-1003
7. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM (1997) The CD95 (APO-1Fas) system mediates drug-induces apoptosis in neuroblastoma cells. Cancer Res 57:3823-3829
8. Herndon D (1995) Toxic epidermal necrolysis: a systemic and dermatologic disorder best treated with standard treatment protocols in burns intensive care units without the prolonged use of corticosteroids. J Am Coll Surg 180:340-342
9. Jarrett P, Rademaker M, Havill J, Pullon H (1997) Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony simulating factor. Clin Exp Dermatol 22:146-147
10. Magina S, Lisboa C, Goncalves E, Conceicao P, Leal U, Mesquita-Guimaraes J (2000) A case of toxic epidermal necrolysis treated with intravenous immunoglobulin. Br J Dermatol 142:177-178
11. Mockenhaupt M, Norgauer J (2002) Cutaneous adverse drug reactions: Stevens-Johnson syndrome and toxic epidermal necrolysis. Allergy Clin Immunol Int 14:143-150
12. Murdoch SR, Fenton DA (1997) Toxic epidermal necrolysis and cyclosporin. Clin Exp Dermatol 22:250-256
13. Paquet P, Arrese Estrada J, Piérard GE (1992) Oral cyclosporin and alopecia aerata. Dermatology 105:314-315
14. Paquet P, Jacob E, Damas P, Piérard GE (2001) Treatment of drug-induced toxic epidermal necrolysis (Lyell's syndrome) with intravenous human immunoglobulins. Burns 27:652-655
15. Paquet P, Piérard GE (1999) Would cyclosporin A be beneficial to mitigate drug-induced toxic epidermal necrolysis? Dermatology 198:198-202
16. Paquet P, Piérard GE (2002) Differential patomechanisms of epidermal necrolytic blistering diseases. Int J Mol Med 10:695-699
17. Paquet P, Piérard GE (2002) Keratinocyte injury in drug-induced toxic epidermal necrolysis: simultaneous but distinct topographic expression of CD95R and calprotectin. Int J Mol Med 10:145-147
18. Paquet P, Piérard GE, Quatresooz P (2005) Novel treatments for drug-induced toxic epidermal necrolysis (Lyell's syndrome). Int Arch Allergy Immunol 136:205-216
19. Phan TG, Wang R, Crotty T, Adelstein S (1999) Toxic epidermal necrolysis treated with intravenous gammaglobulin. Australas J Dermatol 40:153-157
20. Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I et al (2003) Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins. Arch Dermatol 139:26-32
21. Renfro L, Grant-Kels J, Daman LA (1989) Drug-induced toxic epidermal necrolysis treated with cyclosporin. Int J Dermatol 28:441-444
22. Roujeau JC, Guillaume JC, Fabre JP, Penso D, Flechet ML, Girre JP (1990) Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol 126:37-42
23. Sanclemente G, De la Roche C, Escobar C, Fabella R (1998) Pentoxifylline in toxic epidermal necrolysis and Stevens-Johnson syndrome. Int J Dermatol 38:873-874
24. Stella M, Cassano P, Bollero D, Clemente A, Giorio G (2001) Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience. Dermatology 203:45-49
25. Sullivan JR, Watson A (1996) Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management. Australas J Dermatol 37:208-212
26. Szepietowki J, Wasik F, Szybejko-Machay G, May J (1997) Toxic epidermal necrolysis successfully treated with cyclosporin. Report of three cases. J Eur Acad Dermatol Venereol 9:169-172
27. Trautmann A, Akdis M, Schmid-Grendelmeier P, Disch R, Bröcker EB, Blaser K et al (2001) Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis. J Allergy Clin Immunol 108:839-846
28. Trent JT, Kirsner RS, Romanelli P, Kerdel FA (2003) Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN. Arch Dermatol 139:39-43
29. Tristani-Firouzi P, Petersen M, Saffle JR, Morris SE, Zone JJ (2002) Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 47:548-552
30. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D et al (1998) Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282:490-493
31. Wolkenstein P, Latarjet P, Roujeau JC (1998) Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 352:1586-1589
32. Zaki I, Patel S, Reed R, Dalziel KL (1995) Toxic epidermal necrolysis associated with severe hypocalcaemia, and treated with cyclosporin. Br J Dermatol 133:337-338